1. Clinical Trial End Points for Hemodialysis Vascular Access
- Author
-
Thomas S. Huber, Jack Work, Terry Litchfield, Charmaine E. Lok, Surendra Shenoy, Gerald A. Beathard, Deborah Brouwer-Maier, Laura M. Dember, Michael Allon, Melissa West, Prabir Roy-Chaudhury, Celeste Castillo Lee, Haimanot Wasse, and Mark Glickman
- Subjects
Vascular grafting ,medicine.medical_specialty ,Biomedical Research ,Heel ,Endpoint Determination ,Epidemiology ,medicine.medical_treatment ,Interdisciplinary Research ,030232 urology & nephrology ,Public-Private Sector Partnership ,Vascular access ,Arteriovenous fistula ,030204 cardiovascular system & hematology ,Critical Care and Intensive Care Medicine ,Public-Private Sector Partnerships ,03 medical and health sciences ,Arteriovenous Shunt, Surgical ,Catheters, Indwelling ,0302 clinical medicine ,Renal Dialysis ,medicine ,Humans ,Complication rate ,Clinical Trials as Topic ,Transplantation ,business.industry ,medicine.disease ,Surgery ,Clinical trial ,medicine.anatomical_structure ,Nephrology ,Vascular Grafting ,Hemodialysis ,business ,Moving Points in Nephrology - Abstract
Hemodialysis vascular access is the “lifeline” for patients on hemodialysis. Unfortunately, because of its poor patency and significant complication rate, it is also the “Achilles heel” of hemodialysis. For example, the current unassisted arteriovenous fistula (AVF) maturation rate is only
- Published
- 2018